eMedicine Specialties > Cardiology > Arrhythmias

Lown-Ganong-Levine Syndrome

Author: Daniel M Beyerbach, MD, PhD,, Consulting Staff, Florida Electrophysiology Associates; Affiliate Clinical Assistant Professor of Biomedical Science, Florida Atlantic University, Regional Campus of University of Miami Miller School of Medicine
Coauthor(s): Christopher Cadman, MD, Director of Arrhythmia Service, Assistant Professor, Department of Internal Medicine, Division of Cardiology, University of New Mexico
Contributor Information and Disclosures

Updated: Sep 4, 2009

Introduction

Background

The Lown-Ganong-Levine syndrome (LGL) is a clinical syndrome consisting of paroxysms of tachycardia and electrocardiogram (ECG) findings of a short PR interval and normal QRS duration. LGL is usually categorized in a class of preexcitation syndromes that includes the Wolff-Parkinson-White syndrome (WPW), LGL, and Mahaim-type preexcitation. Investigations into WPW have revealed that an accessory pathway for conduction, called a bundle of Kent, from the atria to the ventricles underlies the preexcitation observed in patients with WPW. Less is known regarding the structural anomalies underlying LGL. Theories proposed to explain LGL have centered around the possible existence of intranodal or paranodal fibers that bypass all or part of the atrioventricular (AV) node.

In 1938, Clerc, Levy, and Critesco first described the occurrence of frequent paroxysms of tachycardia in patients with a short PR interval and normal QRS duration.1 This syndrome was again described in 1952 by Lown, Ganong, and Levine, whose names form the eponym now used to describe it.2 In 1946, Burch and Kimball proposed that an atrio-Hisian (AH) pathway might explain the findings of the syndrome, although no such pathway had yet been identified anatomically.3 In 1961, James described fibers that originate in the low atrium and terminate low in the AV node.4 Brechenmacher et al reported anatomic findings of an AH bundle in 1974.5 Subsequent investigations into the origin of LGL have largely involved invasive electrophysiologic studies that have sought to identify structural and functional anomalies that might explain the findings of LGL.6

Criteria for LGL include a PR interval less than or equal to 0.12 second (120 ms), normal QRS complex duration of less than 120 ms, and occurrence of a clinical tachycardia.2,7,8

Historically, some authors have referred to patients with a short PR interval and normal QRS duration as having LGL. However, this practice has been largely abandoned as more evidence has accumulated demonstrating that such patients without a history of tachycardia likely fall into a class of normal variants. Patients with an isolated finding of short PR interval may be characterized as having accelerated atrioventricular nodal conduction.

The term enhanced atrioventricular nodal conduction (EAVNC) refers to a set of functional criteria that includes an AH interval less than or equal to 60 ms, 1-to-1 AV nodal conduction at rates as high as 200 beats per minute, and an abnormally small increase in AH interval as atrial pacing rate is increased.9

EAVNC represents a functional characterization of the AV node, whereas LGL refers to a syndrome of supraventricular tachycardia in association with a short PR interval. The short PR interval in LGL may be related to the presence of EAVNC. LGL and EAVNC may coexist, or either may exist alone in a given patient.

Pathophysiology

The syndrome described by Lown, Ganong, and Levine in 1952 associated the occurrence of tachycardia with presence of a short PR interval and normal QRS. Subsequent investigations have failed to identify a unifying anatomic basis that accounts for both occurrence of tachycardia and presence of a short PR interval. Rather, several mechanisms have been proposed for the coexistence of a short PR interval and normal QRS10,11,12 , while the occurrence of tachycardias has separately been found to be largely based on previously identified conditions, such as AV nodal reentry tachycardia, atrial fibrillation, and ventricular tachycardia.13,14

No single structural anomaly has been implicated directly as the cause of the short PR interval and normal QRS in LGL. Indeed, most authors believe that LGL does not exist as a phenomenon separate from other known conditions. Several structural anomalies have been proposed as the possible basis for LGL,15,16 including the presence of James fibers,17 Mahaim fibers,18 Brechenmacher-type fibers,5 and an anatomically underdeveloped (hypoplastic)19 or small AV node.20,13

James fibers run from the upper portion of the AV node and insert into the lower portion of the AV node, or into the bundle of His.4 Thus, conduction over James fibers bypasses some of the intrinsic AV nodal delay, which shortens the PR interval; the QRS configuration remains normal, as ventricular activation occurs normally via His-Purkinje system. 

Mahaim fibers are muscular bridges, almost exclusively right-sided in occurrence, that may originate in the lower portion of the AV node, the upper portion of the bundle of His, or the bundle branches. Mahaim fibers terminate in the interventricular septum or in a bundle branch. 

Brechenmacher described fibers that run from the atrium to the His bundle, bypassing the AV node altogether. 

Each of these fibers has been identified histologically. However, none of these anomalous communications has been uniquely linked to the presence of LGL. Moreover, the histologic presence of fibers does not speak to whether these fibers are functional, with conductive properties.

EAVNC has been investigated as a possible functional basis for LGL.21 The criteria for EAVNC were established arbitrarily on the basis of observations of some patients with what seemed to be abnormally rapid AV nodal conduction times. However, in 1980, Bauernfeind and colleagues described a unimodal distribution of PR intervals in a series of 65 patients with AV nodal reentrant tachycardia.22  

Further, in 1983 Jackman et al provided convincing evidence that EAVNC does not exist as a phenomenon separate from normal AV nodal physiology, but that AV nodal conduction physiology comprises a spectrum of AH intervals.9 In their series of 160 consecutive patients, they failed to identify a distinct group of patients with abnormally rapid AV nodal conduction. Rather, they found a broad spectrum of AH intervals in a unimodal, continuous distribution. Importantly, among patients with dual pathways, patients with shorter AH intervals do have a greater likelihood of developing AV nodal reentrant tachycardia.23

The modern view of LGL is that no convincing evidence suggests that this is a syndrome separate from other known phenomena. LGL was identified as a clinical syndrome prior to the advent of catheter-based electrophysiologic (EP) studies. EP studies and histopathologic studies have identified several underlying mechanisms that can account for the presence of a short PR interval and normal QRS. These mechanisms include enhanced AV nodal conduction, several types of fibers that bypass all or part of the AV node, and an anatomically small AV node. Studies incorporating electrophysiologic data have separately identified several types tachycardias that occur in patients with LGL. The most common tachycardias include AV nodal reentry, accessory pathway mediated tachycardia, atrial fibrillation, atrial flutter, and ventricular tachycardia.24,21  

To date, the underlying mechanisms that generate a short PR interval in LGL have not been found to be necessary for the development of the tachycardias identified in patients with LGL. In the case of enhanced AV nodal conduction, the short PR interval reflects anterograde conduction over the fast AV nodal pathway; however, during the most common form of AV nodal reentry, which is the most common tachycardia in patients with LGL, conduction occurs anterograde over the AV nodal slow pathway and retrograge up the AV nodal fast pathway. 

Enhanced conduction over the fast pathway is not necessary for existence of the tachycardia (normal fast pathway conduction would suffice). Even the rate of the tachycardia is largely determined by slow pathway conduction, which is independent of the short PR interval mechanism.22  Similarly, the presence of fibers that bypass all or part of the AV node is not necessary for the occurrence of atrial fibrillation or atrial flutter; functionally, these fibers may facilitate more rapid conduction of atrial arrhythmias to the ventricles. 

In summary, LGL is a clinical diagnosis born of the era before EP study. Many mechanisms have been identified to describe the coexistence of a short PR interval and normal QRS and many tachycardias have been identified in patients with LGL. However, none of the identified short PR interval mechanisms is necessary for the generation of LGL tachycardias.

Frequency

United States

Lown and associates described tachyarrhythmias in 17% of patients with a short PR interval.2 Some 2-4% of the adult population has a PR interval less than or equal to 0.12 second.21 Taken together, these data provide an estimate of the frequency of LGL as 0.5% of the adult population.

International

Frequency mirrors that in the United States.

Mortality/Morbidity

Paroxysms of tachycardia represent the primary morbidity of LGL. Few data are available regarding the frequency of these paroxysms. Data regarding mortality from LGL are scant. In their original report, Lown, Ganong, and Levine reported 6 patients with paroxysmal atrial fibrillation, 2 of whom suffered sudden cardiac death.2  Numbers in published studies are too small to estimate mortality rate with significant accuracy or confidence. In the absence of significant structural heart disease, the mortality rate appears to be very low.

Sex

In their 1952 manuscript, Lown, Ganong, and Levine reported 70.9% of their 34 cases to have occurred in women.2

Age

The average age of onset of tachycardia in LGL is 33.5 years.2

Clinical

History

Symptoms of paroxysmal tachycardia must be elicited. Manifestations of such paroxysms include palpitations, lightheadedness, and shortness of breath. In cases of underlying structural heart disease or coronary artery disease, episodes of tachycardia may induce cardiac stress and produce symptoms of chest pain or possibly of hypotension or other hemodynamic instability. At higher ventricular rates, syncope may occur, particularly if ventricular tachycardia or ventricular fibrillation are initiated.

Physical

An accentuated first heart sound of mitral valve closure may be present in 87% of cases.2  During paroxysms of tachycardia, cardiovascular examination may reveal a rapid heart rate. Absence of a rapid heart rate does not exclude LGL as a possible diagnosis, as the tachycardia of LGL is paroxysmal.

Causes

No environmental factors that contribute to occurrence of LGL have been identified. Some evidence suggests that both WPW and LGL may be hereditary in certain families.

More on Lown-Ganong-Levine Syndrome

Overview: Lown-Ganong-Levine Syndrome
Differential Diagnoses & Workup: Lown-Ganong-Levine Syndrome
Treatment & Medication: Lown-Ganong-Levine Syndrome
Follow-up: Lown-Ganong-Levine Syndrome
Multimedia: Lown-Ganong-Levine Syndrome
References

References

  1. Clerc A, Levy R, Critesco C. A propos du raccourcissement permanent de l'espace P-R de l'electrocardiogramme sans deformation du complex ventriculaire. Arch Mal Coeur. 1938;31:569.

  2. LOWN B, GANONG WF, LEVINE SA. The syndrome of short P-R interval, normal QRS complex and paroxysmal rapid heart action. Circulation. May 1952;5(5):693-706. [Medline].

  3. Burch GE, Kimball JL. Notes on the similarity of QRS complex configuration in Wolff-Parkinson-White syndrome. Am Heart J. 1946;32:560.

  4. James TN. Morphology of the human atrioventricular node, with remarks pertinent to its electrophysiology. Am Heart J. 1961;62:756-71.

  5. Brechenmacher C, Laham J, Iris L, et al. [Histological study of abnormal conduction pathways in the Wolff-Parkinson-White syndrome and Lown-Ganong-Levine syndrome]. Arch Mal Coeur Vaiss. May 1974;67(5):507-19. [Medline].

  6. Josephson ME, Kastor JA. Supraventricular tachycardia in Lown-Ganong-Levine syndrome: atrionodal versus intranodal reentry. Am J Cardiol. Oct 1977;40(4):521-7. [Medline].

  7. Chou TC. Wolff-Parkinson-White syndrome and its variants. In: Electrocardiography in Clinical Practice, Adult and Pediatric. 4th ed. Philadelphia:. WB Saunders Co;1996.

  8. Moller P. Letter: Criteria for the LGL syndrome. Am Heart J. Apr 1976;91(4):539-41. [Medline].

  9. Jackman WM, Prystowsky EN, Naccarelli GV, et al. Reevaluation of enhanced atrioventricular nodal conduction: evidence to suggest a continuum of normal atrioventricular nodal physiology. Circulation. Feb 1983;67(2):441-8. [Medline].

  10. Ward DE, Camm AJ, Spurrell RA. Re-entrant tachycardia using two bypass tracts and excluding AV node in short PR interval, normal QRS syndrome. Br Heart J. Oct 1978;40(10):1127-33. [Medline].

  11. Zipes DP, DeJoseph RL, Rothbaum DA. Unusual properties of accessory pathways. Circulation. Jun 1974;49(6):1200-11. [Medline].

  12. Ward DE, Camm AJ, Spurrell RAJ. Dual AH pathways in patients with and without the Lown-Ganong-Levine syndrome. Br Heart J. 1981;45:356.

  13. Benditt DG, Pritchett LC, Smith WM, et al. Characteristics of atrioventricular conduction and the spectrum of arrhythmias in lown-ganong-levine syndrome. Circulation. Mar 1978;57(3):454-65. [Medline].

  14. Denes P, Wu D, Dhingra RC, et al. Demonstration of dual A-V nodal pathways in patients with paroxysmal supraventricular tachycardia. Circulation. Sep 1973;48(3):549-55. [Medline].

  15. Mandel WJ, Danzig R, Hayakawa H. Lown-Ganong-Levine syndrome. A study using His bundle electrograms. Circulation. Oct 1971;44(4):696-708. [Medline].

  16. Douglas JE, Mandel WJ, Danzig R, Hayakawa H. Lown-Ganong-Levine syndrome. Circulation. May 1972;45(5):1143-4. [Medline].

  17. Durrer D, Schuilenburg RM, Wellens HJ. Pre-excitation revisited. Am J Cardiol. Jun 1970;25(6):690-7. [Medline].

  18. Mahaim I. Kent fibers and the A-V paraspecific conduction through the upper connections of the bundle of His-Tawara. Am Heart J. 1947;33:651.

  19. Ometto R, Thiene G, Corrado D, et al. Enhanced A-V nodal conduction (Lown-Ganong-Levine syndrome) by congenitally hypoplastic A-V node. Eur Heart J. Nov 1992;13(11):1579-84. [Medline].

  20. Caracta AR, Damato AN, Gallagher JJ, et al. Electrophysiologic studies in the syndrome of short P-R interval, normal QRS complex. Am J Cardiol. Feb 1973;31(2):245-53. [Medline].

  21. Wiener I. Syndromes of Lown-Ganong-Levine and enhanced atrioventricular nodal conduction. Am J Cardiol. Sep 1 1983;52(5):637-9. [Medline].

  22. Bauernfeind RA, Ayres BF, Wyndham CC, et al. Cycle length in atrioventricular nodal reentrant paroxysmal tachycardia with observations on the Lown-Ganong-Levine syndrome. Am J Cardiol. Jun 1980;45(6):1148-53. [Medline].

  23. Bauernfeind RA, Swiryn S, Strasberg B, et al. Analysis of anterograde and retrograde fast pathway properties in patients with dual atrioventricular nodal pathways: observations regarding the pathophysiology of the Lown-Ganong-Levine syndrome. Am J Cardiol. Feb 1 1982;49(2):283-90. [Medline].

  24. Ward DE, Camm J. Mechanisms of junctional tachycardias in the Lown-Ganong-Levine syndrome. Am Heart J. Jan 1983;105(1):169-75. [Medline].

Further Reading

Keywords

Lown-Gangong-Levine syndrome, LGL syndrome, Clerc-Levy-Critesco syndrome, enhanced atrioventricular nodal conduction, accelerated atrioventricular nodal conduction, short PR/normal QRS syndrome, short PR/narrow QRS syndrome, accessory pathway, WPW syndrome, Wolff-Parkinson-White syndrome

Contributor Information and Disclosures

Author

Daniel M Beyerbach, MD, PhD,, Consulting Staff, Florida Electrophysiology Associates; Affiliate Clinical Assistant Professor of Biomedical Science, Florida Atlantic University, Regional Campus of University of Miami Miller School of Medicine
Daniel M Beyerbach, MD, PhD, is a member of the following medical societies: American College of Cardiology
Disclosure: Nothing to disclose.

Coauthor(s)

Christopher Cadman, MD, Director of Arrhythmia Service, Assistant Professor, Department of Internal Medicine, Division of Cardiology, University of New Mexico
Christopher Cadman, MD is a member of the following medical societies: American College of Cardiology and Phi Beta Kappa
Disclosure: Nothing to disclose.

Medical Editor

Justin D Pearlman, MD, PhD, ME, MA, Director of Advanced Cardiovascular Imaging, Professor of Medicine, Professor of Radiology, Adjunct Professor, Thayer Bioengineering and Computer Science, Dartmouth-Hitchcock Medical Center
Justin D Pearlman, MD, PhD, ME, MA is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Federation for Medical Research, International Society for Magnetic Resonance in Medicine, and Radiological Society of North America
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Frank M Sheridan, MD, Cardiology, Providence Everett Medical Center
Frank M Sheridan, MD is a member of the following medical societies: American College of Cardiology, American Heart Association, and Society for Cardiac Angiography and Interventions
Disclosure: Nothing to disclose.

CME Editor

Amer Suleman, MD, Consultant in Electrophysiology and Cardiovascular Medicine, Department of Internal Medicine, Division of Cardiology, Medical City Dallas Hospital
Amer Suleman, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Institute of Stress, American Society of Hypertension, Federation of American Societies for Experimental Biology, Royal Society of Medicine, and Society of Cardiac Angiography and Interventions
Disclosure: Nothing to disclose.

Chief Editor

Michael E Zevitz, MD, Assistant Professor of Medicine, Finch University of the Health Sciences, The Chicago Medical School; Consulting Staff, Private Practice
Michael E Zevitz, MD is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Medical Association, and Michigan State Medical Society
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.